Journal of Neuroimmunology
Volume 223, Issue 1 , Pages 5-12 , June 2010

Antibodies to gangliosides and ganglioside complexes in Guillain–Barré syndrome and Fisher syndrome: Mini-review

  • Kenichi Kaida

      Affiliations

    • Division of Neurology, Department of Internal Medicine 3, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama-ken, 359-8513, Japan
    • ,
  • Susumu Kusunoki

      Affiliations

    • Department of Neurology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 72 366 0221x3553; fax: +81 72 368 4846.

Received 30 November 2009 ,Revised 1 February 2010 ,Accepted 2 February 2010.

References 

  1. Ang CW, Yuki N, Jacobs BC, Koga M, Van Doorn PA, Schmitz PI, et al. Rapidly progressive, predominantly motor Guillain–Barré syndrome with anti-GalNAc-GD1a antibodies. Neurology. 1999;53:2122–2127
  2. Arasaki K, Kusunoki S, Kudo N, Kanazawa I. Acute conduction block in vitro following exposure to antiganglioside sera. Muscle Nerve. 1993;16:587–593
  3. Buchwald B, Zhang G, Vogt-Eisele AK, Zhang W, Ahangari R, Griffin JW, et al. Anti-ganglioside antibodies alter presynaptic release and calcium influx. Neurobiol. Dis. 2007;28:113–121
  4. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann. Neurol. 1992;31:677–679
  5. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain–Barré syndrome: clinical and immunohistochemical studies. Neurology. 1993;43:1911–1917
  6. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res. 1997;745:32–36
  7. Corbo M, Quattrini A, Latov N, Hays AP. Localization of GM1 and Gal(beta 1–3)GalNAc antigenic determinants in peripheral nerve. Neurology. 1993;43:809–814
  8. Dilley A, Gregson NA, Hadden RD, Smith KJ. Effects on axonal conduction of anti-ganglioside sera and sera from patients with Guillain–Barre syndrome. J. Neuroimmunol. 2003;139:133–140
  9. Gong Y, Tagawa Y, Lunn MP, Laroy W, Heffer-Lauc M, Li CY, et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain. 2002;125:2491–2506
  10. Goodfellow JA, Bowes T, Sheikh K, Odaka M, Halstead SK, Humphreys PD, et al. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J. Neurosci. 2005;25:1620–1628
  11. Goodyear CS, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, et al. Monoclonal antibodies raised against Guillain–Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle–nerve preparations. J. Clin. Invest. 1999;104:697–708
  12. Greenshields KN, Halstead SK, Zitman FM, Rinaldi S, Brennan KM, O'Leary C, et al. The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J. Clin. Invest. 2009;119:595–610
  13. Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, McKhann GM, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann. Neurol. 1996;39:625–635
  14. Hafer-Macko C, Hsieh ST, Li CY, Ho TW, Sheikh K, Cornblath DR, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann. Neurol. 1996;40:635–644
  15. Hakomori S. Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain. Glycoconj. J. 2000;17:143–151
  16. Hakomori S. Carbohydrate-to-carbohydrate interaction, through glycosynapse, as a basis of cell recognition and membrane organization. Glycoconj. J. 2004;21:125–137
  17. Halstead SK, O'Hanlon GM, Humphreys PD, Morrison DB, Morgan BP, Todd AJ, et al. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain. 2004;127:2109–2123
  18. Halstead SK, Humphreys PD, Goodfellow JA, Wagner ER, Smith RA, Willison HJ. Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann. Neurol. 2005;58:203–210
  19. Hao Q, Saida T, Yoshino H, Kuroki S, Nukina M, Saida K. Anti-GalNAc-GD1a antibody-associated Guillain–Barré syndrome with a predominantly distal weakness without cranial nerve impairment and sensory disturbance. Ann. Neurol. 1999;45:758–768
  20. Hirakawa M, Morita D, Tsuji S, Kusunoki S. Effects of phospholipids on antiganglioside antibody reactivity in GBS. J. Neuroimmunol. 2005;159:129–132
  21. Hirota N, Kaji R, Bostock H, Shindo K, Kawasaki T, Mizutani K, et al. The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons. Brain. 1997;120:2159–2169
  22. Ho TW, Willison HJ, Nachamkin I, Li CY, Veitch J, Ung H, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain–Barré syndrome. Ann. Neurol. 1999;45:168–173
  23. Ilyas AA, Li SC, Chou DK, Li YT, Jungalwala FB, Dalakas MC, et al. Gangliosides GM2, IV4GalNAcGM1b, and IV4GalNAcGC1a as antigens for monoclonal immunoglobulin M in neuropathy associated with gammopathy. J. Biol. Chem. 1988;263:4369–4373
  24. Jacobs BC, van Doorn PA, Schmitz PI, Tio-Gillen AP, Herbrink P, Visser LH, et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain–Barré syndrome. Ann. Neurol. 1996;40:181–187
  25. Kaida K, Kusunoki S, Kamakura K, Motoyoshi K, Kanazawa I. Guillain-Barré syndrome with IgM antibody to the ganglioside GalNAc-GD1a. J. Neuroimmunol. 2001;113:260–267
  26. Kaida K, Kusunoki S. Guillain–Barré syndrome — update on immunobiology and treatment. Expert Rev. Neurother. 2009;9:1307–1319
  27. Kaida K, Kusunoki S, Kamakura K, Motoyoshi K, Kanazawa I. Guillain–Barre syndrome with antibody to a ganglioside, N-acetylgalactosaminyl GD1a. Brain. 2000;123:116–124
  28. Kaida K, Kusunoki S, Kamakura K, Motoyoshi K, Kanazawa I. GalNAc-GD1a in human peripheral nerve. Target sites of anti-ganglioside antibody. Neurology. 2003;61:465–470
  29. Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, Hirakawa M, et al. Ganglioside complexes: as new target antigens in Guillain–Barré syndrome. Ann. Neurol. 2004;56:567–571
  30. Kaida K, Kanzaki M, Morita D, Kamakura K, Motoyoshi K, Hirakawa M, et al. Anti-ganglioside complex antibodies in Miller Fisher syndrome. J. Neurol. Neurosurg. Psychiatry. 2006;77:1043–1046
  31. Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, Hirakawa M, et al. Anti-ganglioside complex antibodies associated with severe disability in GBS. J. Neuroimmunol. 2007;182:212–218
  32. Kaida K, Kamakura K, Ogawa G, Ueda M, Motoyoshi K, Arita M, et al. GD1b-specific antibody induces ataxia in Guillain–Barré syndrome. Neurology. 2008;71:196–201
  33. Kaida K, Sonoo M, Ogawa G, Kamakura K, Ueda-Sada M, Arita M, et al. GM1/GalNAc-GD1a complex: a target for pure motor Guillain–Barré syndrome. Neurology. 2008;71:1683–1690
  34. Kaida K, Ariga T, Yu RK. Antiganglioside antibodies and their pathophysiological effects on Guillain–Barré syndrome and related disorders—a review. Glycobiology. 2009;19:676–692
  35. Kanzaki M, Kaida K-I, Ueda M, Morita D, Hirakawa M, Motoyoshi K, et al. Ganglioside complexes containing GQ1b as targets in Miller Fisher and Guillain–Barré syndromes. J. Neurol. Neurosurg. Psychiatry. 2008;79:1148–1152
  36. Koga M, Tatsumoto M, Yuki N, Hirata K. Range of cross reactivity of anti-GM1 IgG antibody in Guillain–Barré syndrome. J. Neurol. Neurosurg. Psychiatry. 2001;71:123–124
  37. Koga M, Yoshino H, Morimatsu M, Yuki N. Anti-GT1a IgG in Guillain–Barré syndrome. J. Neurol. Neurosurg. Psychiatry. 2002;72:767–771
  38. Kuijf ML, Godschalk PC, Gilbert M, Endtz HP, Tio-Gillen AP, van Ang CW, et al. Origin of ganglioside complex antibodies in Guillain–Barré syndrome. J. Neuroimmunol. 2007;188:69–73
  39. Kusunoki S, Chiba A, Tai T, Kanazawa I. Localization of GM1 and GD1b antigens in the human peripheral nervous system. Muscle Nerve. 1993;16:752–756
  40. Kusunoki S, Iwamori M, Chiba A, Hitoshi S, Arita M, Kanazawa I. GM1b is a new member of antigen for serum antibody in Guillain–Barré syndrome. Neurology. 1996;47:237–242
  41. Kusunoki S, Shimizu J, Chiba A, Ugawa Y, Hitoshi S, Kanazawa I. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann. Neurol. 1996;39:424–431
  42. Kusunoki S, Hitoshi S, Kaida K, Arita M, Kanazawa I. Monospecific anti-GD1b IgG is required to induce rabbit ataxic neuropathy. Ann. Neurol. 1999;45:400–403
  43. Kusunoki S, Chiba A, Kanazawa I. Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve. 1999;22:1071–1074
  44. Kuwabara S, Yuki N, Koga M, Hattori T, Matsuura D, Miyake M, et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain–Barré syndrome. Ann. Neurol. 1998;44:202–208
  45. Kuwabara S, Ogawara K, Sung JY, Mori M, Kanai K, Hattori T, et al. Differences in membrane properties of axonal and demyelinating Guillain–Barre syndromes. Ann. Neurol. 2002;52:180–187
  46. Lehmann HC, Lopez PH, Zhang G, Ngyuen T, Zhang J, Kieseier BC, et al. Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model. J. Neurosci. 2007;27:27–34
  47. Liu JX, Willison HJ, Pedrosa-Domellöf F. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest. Ophthalmol. Vis. Sci. 2009;50:3226–3232
  48. Lopez PHH, Schnaar RL. Gangliosides in cell recognition and membrane protein regulation. Curr. Opin. Struct. Biol. 2009;19:1–9
  49. Lopez PH, Zhang G, Bianchet MA, Schnaar RL, Sheikh KA. Structural requirements of anti-GD1a antibodies determine their target specificity. Brain. 2008;131:1926–1939
  50. Lu JL, Sheikh KA, Wu HS, Zhang J, Jiang ZF, Cornblath DR, et al. Physiologic–pathologic correlation in Guillain–Barré syndrome in children. Neurology. 2000;54:33–39
  51. Martin PT. Glycobiology of the neuromuscular junction. J. Neurocytol. 2003;32:915–929
  52. Miyazaki T, Kusunoki S, Kaida K, Shiina M, Kanazawa I. Guillain–Barré syndrome associated with IgG monospecific to ganglioside GD1b. Neurology. 2001;56:1227–1229
  53. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Clinical correlates of serum anti-GT1a IgG antibodies. J. Neurol. Sci. 2004;219:139–145
  54. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal–cervical–brachial variant of Guillain–Barré syndrome. Arch. Neurol. 2007;64:1519–1523
  55. Nakatani Y, Nagaoka T, Hotta S, Utsunomiya I, Yoshino H, Miyatake T, et al. IgG anti-GalNAc-GD1a antibody inhibits the voltage-dependent calcium channel currents in PC12 pheochromocytoma cells. Exp. Neurol. 2007;204:380–386
  56. Nakatani Y, Hotta S, Utsunomiya I, Tanaka K, Hoshi K, Ariga T, et al. Cav2.1 voltage-dependent Ca2+ channel current is inhibited by serum from select patients with Guillain–Barré syndrome. Neurochem. Res. 2009;34:149–157
  57. Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J. Neurol. Neurosurg. Psychiatry. 2001;70:50–55
  58. Ogawa G, Kaida K, Kusunoki S, Ueda M, Kimura F, Kamakura K. Antibodies to ganglioside complexes consisting of asialo-GM1 and GQ1b or GT1a in Fisher and Guillain–Barré syndromes. J. Neuroimmunol. 2009;214:125–127
  59. Ogawa-Goto K, Funamoto N, Abe T, Nagashima K. Different ceramide compositions of gangliosides between human motor and sensory nerves. J. Neurochem. 1990;55:1486–1493
  60. Plomp JJ, Molenaar PC, O'Hanlon GM, Jacobs BC, Veitch J, Daha MR, et al. Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. Ann. Neurol. 1999;45:189–199
  61. Putzu GA, Figarella-Branger D, Bouvier-Labit C, Liprandi A, Bianco N, Pellissier JF. Immunohistochemical localization of cytokines, C5b-9 and ICAM-1 in peripheral nerve of Guillain–Barré syndrome. J. Neurol. Sci. 2000;174:16–21
  62. Rees JH, Gregson NA, Hughes RA. Anti-ganglioside GM1 antibodies in Guillain–Barré syndrome and their relationship to Campylobacter jejuni infection. Ann. Neurol. 1995;38:809–816
  63. Rinaldi S, Brennan KM, Goodyear CS, O'Leary C, Schiavo G, Crocker PR, et al. Analysis of lectin binding to glycolipid complexes using combinatorial glycoarrays. Glycobiology. 2009;19:789–796
  64. Santoro M, Uncini A, Corbo M, Staugaitis SM, Thomas FP, Hays AP, et al. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann. Neurol. 1992;31:385–390
  65. Sheikh KA, Deerinck TJ, Ellisman MH, Griffin JW. The distribution of ganglioside-like moieties in peripheral nerves. Brain. 1999;122:449–460
  66. Simons K, Toomre D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 2000;1:31–39
  67. Susuki K, Nishimoto Y, Yamada M, Baba M, Ueda S, Hirata K, et al. Acute motor axonal neuropathy rabbit model: immune attack on nerve root axons. Ann. Neurol. 2003;54:383–388
  68. Susuki K, Baba H, Tohyama K, Kanai K, Kuwabara S, Hirata K, et al. Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers. Glia. 2007;55:746–757
  69. Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J. Neurosci. 2007;27:3956–3967
  70. Svennerholm L, Månsson JE, Li YT. Isolation and structural determination of a novel ganglioside, a disialosylpentahexosylceramide from human brain. J. Biol. Chem. 1973;248:740–742
  71. Tagawa Y, Laroy W, Nimrichter L, Fromholt SE, Moser AB, Moser HW, et al. Anti-ganglioside antibodies bind with enhanced affinity to gangliosides containing very long chain fatty acids. Neurochem. Res. 2002;27:847–855
  72. Taguchi K, Ren J, Utsunomiya I, Aoyagi H, Fujita N, Ariga T, et al. Neurophysiological and immunohistochemical studies on Guillain–Barré syndrome with IgG anti-GalNAc-GD1a antibodies—effects on neuromuscular transmission. J. Neurol. Sci. 2004;225:91–98
  73. Takada K, Shimizu J, Kusunoki S. Apoptosis of primary sensory neurons in GD1b-induced sensory ataxic neuropathy. Exp. Neurol. 2008;209:279–283
  74. Takigawa T, Yasuda H, Kikkawa R, Shigeta Y, Saida T, Kitasato H. Antibodies against GM1 ganglioside affect K+and Na+currents in isolated rat myelinated nerve fibers. Ann. Neurol. 1995;37:436–442
  75. Todeschini AR, Dos Santos JN, Handa K, Hakomori S-I. Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway. Proc. Natl. Acad. Sci. U. S. A. 2008;105:1925–1930
  76. Varki A. Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins. Nature. 2007;446:1023–1029
  77. Visser LH, Van der Meche FG, Van Doorn PA, Meulstee J, Jacobs BC, Oomes PG, et al. Guillain–Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain–Barré Study Group. Brain. 1995;118:841–847
  78. Wanschitz J, Maier H, Lassmann H, Budka H, Berger T. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain–Barré syndrome. Brain. 2003;126:2034–2042
  79. Weber F, Rudel R, Aulkemeyer P, Brinkmeier H. Anti-GM1 antibodies can block neuronal voltage-gated sodium channels. Muscle Nerve. 2000;23:1414–1420
  80. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002;125:2591–2625
  81. Willison HJ, Halstead SK, Beveridge E, Zitman FM, Greenshields KN, Morgan BP, et al. The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain–Barre syndrome. J. Neuroimmunol. 2008;201–202:172–182
  82. Yuki N, Ang CW, Koga M, Jacobs BC, van Doorn PA, Hirata K, et al. Clinical features and response to treatment in Guillain–Barré syndrome associated with antibodies to GM1b ganglioside. Ann. Neurol. 2000;47:314–321
  83. Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, et al. Animal model of axonal Guillain–Barré syndrome induced by sensitization with GM1 ganglioside. Ann. Neurol. 2001;49:712–720
  84. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain–Barré syndrome. Proc. Natl. Acad. Sci. U. S. A. 2004;101:11404–11409

PII: S0165-5728(10)00041-X

doi: 10.1016/j.jneuroim.2010.02.001

Journal of Neuroimmunology
Volume 223, Issue 1 , Pages 5-12 , June 2010

Article Tools

* Image Usage & Resolution